SAN ANTONIO - As cancer researchers move away from the general use of chemotherapy and into more targeted approaches, scientists are working to discover effective ways to measure response and risk. Data presented at the CTRC-AACR San Antonio Breast Cancer Symposium illustrate the cutting edge of biomarker discovery and development.
Reductions in Breast Density Predict Potential Benefit of Tamoxifen
Abstract #61, Jack Cuzick, Ph.D.
A reduction in breast density of at least 10 percent may predict who benefits from the breast cancer preventive effects of tamoxifen. Researchers studied 1,063 women and found that those with reduced breast density after 12 to 18 months of treatment had a 52 percent reduced risk of breast cancer. By contrast, those women who did not have a decrease in breast density had only an eight percent risk reduction.
Full release available/Complete data to be presented at the meeting
Poor Prognosis on Small, HER2 Positive Tumors
Abstract #701, Ana M. Gonzalez-Angula, M.D
Although current guidelines call for no further therapy after surgery on breast tumors one centimeter or smaller, a new study suggests that if these tumors are HER2 positive patients have an increased risk for relapse. In the largest study of its kind to date (n=1,315, including a validation set), researchers found that the five-year recurrence rate was 23 percent among patients with small HER2-positive tumors, compared with eight percent in other tumor types.
Full release available/Complete data to be presented at the meeting
New Genetic Modeling Improves Screening
Abstract #502, Kathie Dalessandri, M.D.
A new genetic model based on 22 single nucleotide polymorphisms may improve the ability to predict risk of developing breast cancer. Researchers found that in a high-risk population from Marin County, California, this model improved diagnostic accuracy by
'/>"/>
| Contact: Jeremy Moore Jeremy.moore@aacr.org 267-646-0557 American Association for Cancer Research Source:Eurekalert |